NantKwest
  • About
    • Company
    • Leadership
    • Board of Directors
  • Technology
    • Platform
    • Manufacturing
    • haNK
    • taNK
    • t-haNK
    • Posters
    • Publications
  • Clinical Trials
    • Pipeline
    • Nant Cancer Vaccine
  • News
    • Press Releases
    • Articles
    • Events
    • Presentations
  • Investors
    • Overview
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Stock Calculator
    • News
    • Events & Presentations
    • Financials
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Highlights
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • Contact Us
  • Careers
    • Join Our Kwest
    • We’re Hiring
  • Contact
  • Patients
Select Page

haNK + Herceptin (grey) specifically kills HER2 expressing target cancer cells (red)

NantKwest-NK-92-Authenticity-Stamp

CONTACT NANTKWEST

line
Brink-Biologics-NK-92-Authenticity-Stamp

NK-92 ®️ CELLS FOR ASSAYS

  • Facebook
  • Twitter

  © 2020 NantKwest. All Rights Reserved. A member of the NantWorks ecosystem of companies Privacy Policy | Legal Notice | Patent Notice
‘Nantkwest’, ‘aNK’, 'haNK', 'taNK', ‘vaNK’, 't-haNK', 'NK-92', ‘Neukosome’, 'Living Drugs in a Bag', and ‘Nature’s First Responder’ are trademarks or registered trademarks of Nantkwest, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.